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Background: Although a number of growth factors bind cell-surface heparan
sulphate proteoglycans (HSPGs), the role of this interaction is unclear except
for fibroblast growth factor which requires HSPG binding for signalling.
Hepatocyte growth factor/scatter factor (HGF/SF) plays important roles in
mammalian development and tissue regeneration and acts on target cells
through a specific receptor tyrosine kinase encoded by the c-met proto-
oncogene. This factor also binds HSPGs with high affinity, but conflicting data
have been reported on the role of HSPG binding in HGF/SF signalling. 
Results: To map the binding sites for HSPG and the Met receptor in HGF/SF,
we have engineered a number of HGF/SF mutants in which several clusters of
solvent-accessible residues in the hairpin structure of the amino-terminal
domain or in kringle 2 have been replaced. Two of the mutants (HP1 and HP2)
showed greatly decreased (more than 50-fold) affinity for heparin and HSPGs
but retained full mitogenic and motogenic activities on target cells in culture.
Furthermore, when compared with wild-type HGF/SF, the HP1 mutant exhibited
a delayed clearance from the blood, higher tissue levels and a higher induction
of DNA synthesis in normal, adult murine liver. 
Conclusions: These results establish the following: the binding sites in
HGF/SF for Met and for HSPGs can be dissociated by protein engineering;
high-affinity binding of HGF/SF to HSPGs is not essential for signalling; one
role of HSPG binding in the HGF/SF system appears to be sequestration and
degradation of the growth factor; and HGF/SF mutants with decreased affinity
for HSPGs exhibit enhanced activity in vivo.
Background
Polypeptide growth factors are known to exert their
effects on target cells by binding to specific membrane
receptors [1]. However, it has become clear in recent years
that a number of these proteins also bind cell-surface and
matrix proteoglycans, especially those of the heparan sul-
phate variety (HSPGs). The biological significance of this
dual interaction is well understood in the case of fibroblast
growth factor (FGF): cells expressing the FGF receptor
but lacking membrane-bound heparan sulphate fail to
respond to basic FGF [2,3], suggesting that heparan sul-
phate is an essential co-receptor for FGF signalling. Other
growth factors, such as the epidermal growth factor
(EGF)-related polypeptides amphiregulin [4] and
heparin-binding EGF (HB-EGF) [5], as well as several
splice variants of vascular endothelial growth factor
(VEGF) [6] also require cell-bound heparan sulphate for
activity, although the role of HSPGs in these systems is
less defined.
Hepatocyte growth factor/scatter factor (HGF/SF) [7–12] is
a high molecular weight polypeptide growth factor with a
domain structure related to that of the blood proteinase
precursor plasminogen. Like plasminogen, HGF/SF is pro-
duced as an inactive, single-chain polypeptide which is
converted proteolytically into an active two-chain species
[13–15]. This form of HGF/SF induces growth, movement
and differentiation in target cells via a specific membrane
tyrosine-kinase receptor encoded by the c-met proto-onco-
gene [16,17]. HGF/SF binds tightly to the Met receptor
with a molar dissociation constant (Kd) in the sub-nano-
molar range [18,19]. HGF/SF also binds heparin [20,21], a
densely sulphated glycosaminoglycan that resembles the
carbohydrate side chains of HSPGs. Binding to heparin
does not appear to affect the affinity of HGF/SF for a
soluble form of the Met receptor although it does increase
receptor phosphorylation and mitogenicity on target cells
[22]. HGF/SF–heparin complexes also have sustained
plasma levels and reduced hepatic clearance in vivo [23].
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The modular structure of HGF/SF has facilitated the
identification of the domains responsible for binding to
the receptor and to heparin. Deletion of the hairpin struc-
ture of the amino-terminal domain (a domain homologous
to the activation peptide of plasminogen) or kringle 2 (a
globular domain with a characteristic triple-looped struc-
ture) results in mutants with reduced apparent affinities
for heparin [24]. By contrast, deletion of kringle 1, 3 or 4 or
the proteinase domain, has little or no effect [24]. Thus,
the heparin-binding site(s) of HGF/SF appear to be con-
tained in the hairpin structure of the amino-terminal
domain and kringle 2. The same domains, however, are
also critical for Met binding and signalling [25–28].
In order to dissect the binding sites for Met and heparin in
HGF/SF, we generated three-dimensional models of the
individual domains [29] to help to design a number of site-
specific HGF/SF mutants. The available X-ray structures
of antithrombin [30] and FGF–heparin complexes [31]
indicate that heparin-binding sites are composed primarily
of clusters of positively charged residues making electro-
static contact with negatively charged groups in the glycos-
aminoglycan. We therefore searched the surface of the
hairpin structure and kringle 2 of HGF/SF for clusters of
positively charged amino acids, identified three such clus-
ters (two in the hairpin structure and one in kringle 2) and
introduced specific mutations at these sites.
Results
Hairpin structure and kringle 2 mutants of HGF/SF
The amino-terminal domain of HGF/SF contains four cys-
teine residues that are conserved in the HGF/SF homo-
logues hepatocyte growth factor-like/macrophage-stimulating
protein (HGFl/MSP) and plasminogen. Studies of plas-
minogen [32] indicate that this domain forms a hairpin
structure stabilised by two disulphide bonds. A three-
dimensional model of the hairpin structure of HGF/SF
suggested the presence of several positively charged
residues that were absent in the corresponding models of
HGFl/MSP and plasminogen [29]. Six different point
mutants of the hairpin structure of HGF/SF were con-
structed (HP1–HP6) in which a total of 10 amino acid
residues were substituted. The strategy involved mutation
of positively charged amino acids to negative, negative to
positive and hydrophobic to polar (Figure 1a). The activity
of these point mutants was compared with that of wild-
type (wt) HGF/SF and HP∆, a mutant in which the whole
hairpin structure (amino acids 68–100) was deleted. In
addition, two multiple mutants of kringle 2 were con-
structed (Figure 1b). In the Kr2-1 mutant, a cluster of four
positive residues on the surface of the kringle (H241,
R242, K244 and R249, using single-letter amino-acid
code) was mutated; in the Kr2-2 mutant, three residues
were mutated that had been predicted either to form part
of a hydrophobic pocket on the surface of kringle 2 (W282
and Y284) or to establish hydrogen bonds with a lysine
residue bound within the pocket (R281) [29]. 
For initial studies, mutants were expressed by transient
transfection into the Neuro 2a cell line (Figure 2a) and
characterised for heparin binding (Figure 2b) and biologi-
cal activity (Figure 2c). As expected, HP∆, the mutant
lacking the hairpin structure, exhibited neither heparin
binding nor biological activity. The point mutants were
categorised into three different groups: group 1 (HP1,
HP2 and HP4) had normal signalling activity but a greatly
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Figure 1
Distribution of the electrostatic potential in (a)
the hairpin structure and (b) the kringle 2 of
HGF/SF and the mutations introduced into
these regions. The electrostatic potential on
the solvent-accessible surface of the two
HGF/SF domains is shown by a colour code
ranging from yellow (strong positive charge)
to blue (strong negative charge) using the
molecular interactive display and simulation
(MIDAS) software (UCSF) and the atomic
coordinates of previously generated three-
dimensional models [29]. The mutations
introduced into the hairpin structure and into
kringle 2 are also shown.
HP1: R73E, R76E, R93E  
HP2: R73E, R76E, K78E  
HP3: K91D, R93E, K94D  
HP4: L80S, F82Q  
HP5: K85E 
HP6: D90K 
Kr2-1: H241S, R242E, K244E, R249G  
Kr2-2: R281G, W282A, Y284A 
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decreased (HP1 and HP2) or a moderately decreased
(HP4) heparin-binding ability; group 2 (HP3) showed a
severe loss of both signalling and heparin-binding activity;
and group 3 (HP5 and HP6) behaved essentially like wild-
type HGF/SF (Figure 2b,c). The first kringle 2 mutant,
Kr2-1, showed severely reduced levels of heparin binding
and biological activity whereas the second one, Kr2-2, was
indistinguishable from wt-HGF/SF (Figure 2b,c). From
these results, we can conclude that the first cluster of posi-
tively charged residues in the hairpin structure (R73, R76)
is involved in binding to heparin but not to Met and that
residues R281, W282 and Y284 are not involved in either
process. It also appears that two extra clusters of positively
charged residues, one in the hairpin structure (K91 and
K94) and one in kringle 2 (H241, R242, K244 and R249)
may participate in binding to both Met and heparin. 
Binding kinetics of wt-HGF/SF, HP1 and their NK2
fragments to heparin
Full-length wt-HGF/SF and HP1 (one of the two mutants
that showed greatly reduced heparin binding) were
expressed in insect cells in order to analyse their kinetics
of binding to heparin by surface plasmon resonance (SPR).
These experiments revealed important differences in the
binding kinetics of HP1. 
The binding to heparin of wt-HGF/SF (4–30 nM) exhibited
a single first-order dissociation rate constant (koff) of approx-
imately 1 × 10–3 sec–1. The bulk of the binding during asso-
ciation could be fitted to a single-site model with an
association rate constant (kon) of approximately
1 × 106 M–1 sec–1, giving a Kd of approximately 1 × 10–9 M.
HP1 (4–80 nM) showed much lower levels of heparin
binding (see Supplementary material). We considered,
however, that the difference observed between wt-HGF/SF
and HP1 might have been affected by the presence of
dimeric or oligomeric forms of the two proteins, a factor that
could not be resolved by size-exclusion chromatography
because of low recovery. We therefore expressed the NK2
fragments of wt-HGF/SF and HP1 — which contain all the
domains shown to be involved in heparin binding [24] — in
the methylotropic yeast Pichia pastoris and used these for
further kinetic analysis. The wt-NK2 and HP1-NK2 frag-
ments purified from the supernatant of P. pastoris cultures
consisted of a mixture of NK2 monomers and dimers that
could be separated readily on Superdex-75 columns, allow-
ing the kinetics of binding to heparin to be established
using bona fide monomeric species. 
Sensorgram overlays of the binding of wt-NK2 (Figure 3a)
and HP1-NK2 (Figure 3b) to heparin confirmed that these
fragments had major differences in heparin binding. For
wt-NK2, the dissociation curves were slower at the higher
concentrations and apparent koff values varied between 1
and 4 × 10–3 sec–1 (Figure 3c). In contrast, the dissociation
of HP1-NK2 (Figure 3b) rose with concentration to an
apparent koff value of 6–7 × 10–3 sec–1 (Figure 3c). Analysis
of the association phase of wt-NK2 (Figure 3a) showed
complex kinetics. Assuming a single class of binding sites
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Figure 2
Heparin-binding and MDCK scatter activity of wild-type and mutant
forms of HGF/SF. (a) Expression of wild-type and mutant forms of
HGF/SF. Wild-type and mutant HGF/SF present in the supernatant of
Neuro 2a cells that had been transiently transfected with cDNAs
encoding the proteins indicated above the lanes and then labelled with
[35S]-cysteine were subjected to SDS–PAGE. The migration of the
60 kDa A chain and the 32/34 kDa B chain is indicated. Control
samples are supernatants of Neuro 2a cells transfected with vector
alone. (b) Binding of wild-type or mutant HGF/SFs to heparin. The
data are expressed as a percentage relative to wt-HGF/SF, which is
designated as having 100% activity. Deletion of the hairpin structure
(residues 68–100; HP∆) reduced heparin binding to less than 5%.
Similarily, all mutants in which basic amino acid residues were
exchanged (HP1, HP2, HP3) showed strongly reduced heparin
binding. Mutations outside the positively charged surface (HP4, HP5,
HP6) either had a less pronounced effect (HP4) or no effect (HP5 and
HP6). Substitution of positively charged amino acids on the surface of
kringle 2 (Kr2-1) reduced heparin binding to 18% of wt-HGF/SF
activity, whereas deletion of the lysine-binding pocket (Kr2-2) had no
effect. (c) Scatter of MDCK colonies by wild-type and mutant
HGF/SFs. The data are expressed as a percentage of wt-HGF/SF,
which is designated as having 100% activity. Deletion of the hairpin
structure (HP∆) abolished biological activity but point mutations of
positively charged amino acids in the hairpin structure had variable
effects. The two kringle 2 mutants either showed a severe loss of
activity (Kr2-1) or no change (Kr2-2).
C
on
tr
ol
W
ild
 ty
pe
H
P
∆
C
on
tr
ol
W
ild
 ty
pe
H
P
∆
H
P
1
H
P
4
H
P
5
H
P
6
H
P
2
H
P
3
K
r2
-1
K
r2
-2
A
chain
B
chain 
W
ild
 ty
pe
H
P
∆
H
P
1
H
P
2
H
P
3
H
P
4
H
P
5
H
P
6
K
r2
-1
K
r2
-2
80
60
40
20
0
100
M
D
C
K
 s
ca
tte
r a
ct
iv
ity
H
ep
ar
in
-b
in
di
ng

ac
tiv
ity
80
60
40
20
0
100
(b)
(a)
(c)
Current Biology
and taking data from the earliest (fastest) phase, plots of
the observed association rate constant (‘Ks’) against con-
centration for concentrations up to 300 nM gave a straight
line (r2 = 0.997) from which we calculated kon to be
1.75 × 106 M–1 sec–1 (Figure 3d). In the later stages of
binding, a second phase showing much slower association
was discernible but attempts to fit models that proposed
two distinct classes of binding sites were unsuccessful.
Taking the fastest value for koff to be 4 × 10–3 sec–1 and a
value for kon to be 1.75 × 106 M–1 sec–1, a Kd of 2.3 nM was
calculated for wt-NK2. For HP1-NK2, analysis of the early
phase of binding (assuming the presence of a single class
of binding sites) gave a kon value of approximately
5 × 104 M–1 sec–1 from the plot of KS against concentration
(Figure 3d). This figure was approximately 35-fold lower
than that for wt-NK2. Taking a value of 6 × 10–3 sec–1 for
koff (Figure 3c), a Kd of 120 nM was calculated for HP1-
NK2. The binding affinity of HP1-NK2 is therefore more
than 50-fold lower than that of wt-NK2. 
Binding of wt-HGF/SF and HP1 to HSPGs
The binding of wt-HGF/SF and HP1 to cell-surface and
matrix heparan sulphates was investigated in several cell
types, including the carcinoma lines HepG2 and Hep3B
and mink lung cells. The latter have recently been shown
to bind large amounts of HGF/SF and its truncated forms
NK1 and NK2 via HSPGs [33]. By immunofluorescence,
the total binding of HP1 to HepG2 and Hep3B cells was
much lower than for wt-HGF/SF (compare Figure 4a with
Figure 4b for HepG2 cells, and Figure 4c with Figure 4d
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Figure 3
BIAcore analysis of wt-NK2 and HP1-NK2
binding to immobilised heparin. (a) A
sensorgram overlay of wt-NK2 (10–300 nM)
binding to a heparin surface (maximum
binding capacity 340 resonance units, RU).
(b) A corresponding set of sensorgrams for
HP1-NK2 (10–300 nM; surface capacity
approximately 170 RU). A longer injection
time was used for HP1-NK2 to allow for the
differences in association rates. The spikes at
the beginning and the end of the sample
pulses are artefacts resulting from
subtraction of the curves from the blank
surface (data not shown) and are due to
small, irresolvable timing errors. (c) A plot of
koff against concentration for wt-NK2 and
HP1-NK2. (d) A plot of the observed rate
constant Ks against concentration for wt-NK2
and HP1-NK2.
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Figure 4
Binding of wt-HGF/SF and HP1 to HepG2 and Hep3B cell lines. Total
binding of 100 ng/ml wt-HGF/SF and HP1 to (a,b) HepG2 cells and
(c,d) Hep3B cells as visualised by immunofluorescence. A strong
signal was seen with cells incubated with wt-HGF/SF (a,c) indicating
abundant binding of the factor to the cell surface. Cells incubated with
HP1 samples (b,d) showed reduced levels of staining.
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for Hep3B cells). These results were confirmed and
extended by a quantitative solid-phase assay and a repre-
sentative experiment illustrating the binding of full length
wt-HGF/SF and HP1 to mink lung cells is shown in
Figure 5. The total binding of wt-HGF/SF to mink lung
cells increased steadily from 10 to 675 ng/ml whereas
binding of HP1 was hardly measurable over the same
range of concentrations. Exogenous heparin (0.1 mg/ml)
competed effectively for the binding of wt-HGF/SF to the
cells and reduced this binding to levels only slightly
higher than those for HP1.
Binding of wt-HGF/SF and HP1 to Met and activity on
target cells in culture
In marked contrast with the reduced binding of HP1 to
heparin and cell-associated HSPGs, the binding of HP1 to
a soluble form of the Met receptor and its ability to induce
stimulation of DNA synthesis in mink lung cells were only
marginally lower than for wt-HGF/SF (Figure 6a,b,
respectively). Similar results were obtained with the
mouse keratinocyte line MK (data not shown). Equally,
the ability of HP1 to induce dissociation and scattering of
mink lung cells and Madin–Darby canine kidney
(MDCK) cells were indistinguishable from wt-HGF/SF
(compare Figure 7b with Figure 7c and Figure 7e with
Figure 7f). Thus, in spite of a considerable decrease in
binding affinity for heparin and HSPGs, the ability of the
HP1 mutant to induce DNA synthesis and promote cell
movement of target cells was indistinguishable from
wt-HGF/SF. 
In vivo activity of wt-HGF/SF and HP1 
The reduced binding of HP1 to heparin and HSPGs
prompted us to investigate the effect of the HP1 muta-
tions on the behaviour of HGF/SF in vivo. For this, wt-
HGF/SF and HP1 were labelled with 125I and injected
into the jugular vein of adult rats. The concentration of
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Figure 5
Binding of wt-HGF/SF and HP1 to mink lung cells. Total binding of 
wt-HGF/SF and HP1 to mink lung cells in a 96-well plate. The 
wt-HGF/SF showed strong concentration-dependent binding to the
cell surface of mink lung cells which could be competed by addition of
soluble heparin at 0.1 mg/ml. In contrast, the binding of HP1 was
negligible at concentrations up to 675 ng/ml and was not affected by
the addition of heparin.
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Figure 6
Binding of wt-HGF/SF and HP1 to a soluble form of the Met receptor
(Met–Fc) and effect of wt-HGF/SF and HP1 on DNA synthesis in mink
lung cells. (a) Binding of wt-HGF/SF and HP1 to Met–Fc. Immobilised
wt-HGF/SF or HP1 were incubated with 200 ng/ml Met–Fc and
bound Met–Fc was detected with an anti-human immunoglobulin G
antibody. (b) Effect of wt-HGF/SF and HP1 on DNA synthesis in mink
lung cells. The DNA synthesis elicited by wt-HGF/SF or HP1 after
subtraction of background counts ([3H]-thymidine incorporated by
cultures incubated in control medium) is shown.
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the two proteins in serum and in several organs was then
measured in the form of trichloroacetic acid (TCA)-insolu-
ble radioactivity. Figure 8a shows the clearance curve for
wt-HGF/SF and HP1 from serum. In agreement with pre-
vious studies [23,34,35], we observed a rapid clearance of
wt-HGF/SF from the circulation (more than 98% over the
130 Current Biology, Vol 8 No 3
Figure 7
Effect of wt-HGF/SF and HP1 on the
morphology of mink lung cells and MDCK
cells. (a–c) Mink lung cells and (d–f) MDCK
cells were cultured (a,d) in the absence of
factors or after overnight incubation with (b,e)
20 ng/ml wt-HGF/SF or (c,f) 20 ng/ml HP1.
In control cultures (a,d), cells exhibited a
typical epithelial morphology. The effects of
wt-HGF/SF and HP1 on cell dissociation and
morphology were indistinguishable.
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(c)
Clearance, tissue distribution and activity in vivo of wt-HGF/SF and
HP1. (a) Clearance curves of 125I -labelled wt-HGF/SF and HP1 from
rat serum. Adult rats were injected with either [125I]-labeled wt-HGF/SF
(n = 3) or HP1 (n = 3) in the jugular vein and blood samples taken at
the times shown. The concentration of wt-HGF/SF and HP1 remaining
in serum (TCA-insoluble radioactivity) is shown as a fraction of the total
radioactivity injected. (b) Distribution of [125I]-labelled wt-HGF/SF and
HP1 in rat tissues. Two hours after injection, two animals were
sacrificed and, after perfusion, several organs (liver, kidney, lung, heart,
testis and spleen) were homogenised and the amount of TCA-insoluble
radioactivity measured. The level of tissue radioactivity was 2–3-fold
higher for HP1 than for wt-HGF/SF, although the pattern of organ
distribution was the same with the two proteins. (c) Stimulation of DNA
synthesis in mouse liver by wt-HGF/SF and HP1. The wt-HGF/SF and
HP1 proteins were administered intravenously over a period of 3 days
(total dose 277.5 µg per animal distributed over the course of
five injections). At the time that the animals received the last dose of
factor, bromodeoxyuridine (BrdU) was injected intraperitoneally
(75 µg/g body weight), and 12 h later the animals were sacrificed.
BrdU-labelled cells were counted on frozen liver sections (at least 8
different sections and a total of 120 fields per animal). Data are the
mean ± s.d. for four (wt- HGF/SF) or three (HP1) animals.
first 15 minutes). The clearance of HP1 was much slower
and, at every time point tested, the concentration of HP1
in plasma was 5–10-fold higher than wt-HGF/SF for up to
20 hours after injection (Figure 8a). 
The slower clearance of HP1 from serum was associated
with an increased amount of the mutant factor in several
organs including liver, kidney, lung, heart, testis and
spleen (Figure 8b). The relative distribution of the HP1
mutant and wt-HGF/SF in different organs was similar
but the concentration of HP1 in these organs was 2–3-fold
higher than wt-HGF/SF (Figure 8b). The ability of wt-
HGF/SF to induce DNA synthesis in adult liver was then
investigated after intravenous injection of the two pro-
teins. As expected, in the absence of factors, DNA synthe-
sis was very low but increased considerably after
administration of either HGF/SF or HP1 (Figure 8c).
However, stimulation by HP1 was 2.7-fold higher than for
wt-HGF/SF (Figure 8c), in agreement with the increased
level — decreased clearance — of the factor in serum and
liver (Figure 8a,b). 
Discussion
The heparin-binding sites and receptor-binding sites of
HGF/SF
Previous studies had shown that the small hairpin struc-
ture of the amino-terminal domain of HGF/SF is critical
for binding to both heparin [24] and the Met receptor
[25,27–28]. In this study, we have shown that the binding
sites for heparin and the receptor in HGF/SF can be sepa-
rated by protein engineering and that mutant forms of
HGF/SF that have much lower levels of heparin binding
also have higher biological activity than wt-HGF/SF in
vivo (Figure 8c). Given that both the HP1 (R73E, R76E,
R93E) and HP2 (R73E, R76E, K78E) mutants had a
much lower affinity for heparin but had biological activi-
ties on target cells in culture that were comparable to wt-
HGF/SF, we suggest that the mutations shared by these
mutants (R73E and R76E) are critical for heparin binding,
a conclusion supported by preliminary characterisation of
the R73E,R76E double mutant (G.H., unpublished obser-
vations). In contrast, substitution of a second cluster of
positively charged residues in the hairpin structure (K91,
R93 and K94) or substitution of a separate cluster of posi-
tively charged residues in kringle 2 (H241, R242, K244
and R249) abolished both heparin binding and HGF/SF
signalling in target cells. 
Alanine-scanning mutagenesis of the amino-terminal
domain of HGF/SF failed to identify residues in the
hairpin structure that are essential for Met binding and
signalling [36], possibly because multiple substitutions of
neighbouring residues in the hairpin structure (such as the
ones that we have introduced) are required to produce
measurable changes: heparin-binding activity was not
reported in these studies. Another recent study in which
either R76 and R78 or K91, R93 and K94 were mutated to
alanine residues showed a modest effect on the heparin-
binding activity of the R76A,R78A mutant and no effect
for the K91A,R93A,K94A mutant [37]. It should be noted,
however, that in this study the critical R73 residue was not
mutated and positively charged residues were changed to
alanine rather than to negatively charged residues. These
features most certainly account for the different behaviour
of the set of mutants reported by Sakata and colleagues
[37] and the ones described here, and these aspects
strengthen the emerging role of electrostatic interactions
on association rates [38]. 
Binding kinetics of wt-HGF/SF and its NK2 fragment to
heparin
Our data indicate that full-length wt-HGF/SF binds
heparin with high affinity (Kd = ~1 nM). This figure com-
pares with a value of 50 nM for acidic FGF obtained under
similar experimental conditions [39]. In order to ensure that
the measured kinetics resulted from the interaction of
monomeric protein species with heparin (and thus establish
accurate kinetics for the HP1 mutant), we used monomeric
NK2 fragments expressed in P. pastoris. The dissociation
kinetics of wt-NK2 revealed a significant effect on appar-
ent koff values at the highest concentrations of protein, sug-
gesting co-operative binding of NK2 to heparin (data not
shown). Analysis of the stoichiometry of binding at or near
saturation indicated that approximately four wt-NK2 mole-
cules bound 16 kDa heparin. This value suggests that the
heparin-binding site of NK2 and HGF/SF encompasses
approximately 14 monosaccharide units, which is consistent
with the findings of Lyon et al. [40], who reported that
heparan sulphate fragments of 12–14 units were required
for high-affinity binding to HGF/SF.
Different roles for heparan sulphates in the HGF/SF and
FGF systems
The HP1 mutant has provided a number of insights into
the role of heparin-binding in HGF/SF activity. HGF/SF
is one of a number of growth factors that bind HSPGs, but
the role of heparan sulphate in growth factor activity is
generally not clear except in the case of FGF. For FGF
there is evidence that three components (ligand, receptor
and heparan sulphate) are required for signalling. This
conclusion is supported by transfection experiments [2,3]
and biochemical studies with purified components [41].
HSPGs probably act by inducing the dimerisation of FGF
thus promoting receptor dimerisation and signalling [42],
an interpretation consistent with the recent structures of
FGF–heparin complexes [31].
Our results indicate a different role for HSPGs in the
HGF/SF system. Although two studies have reported that
heparin enhances the activity of NK1 and NK2 fragments
on cells in culture [33,37], we find that the biological activ-
ity of a mutant that lacks high-affinity HSPG-binding
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ability is essentially indistinguishable from wt-HGF/SF.
This result is consistent with data demonstrating that full-
length HGF/SF can mediate a substantial mitogenic
response in cells, such as BaF3, that lack HSPGs [33] and
suggest that, whereas NK1 and NK2 fragments may
require HSPGs for agonistic activity [33,37], this is not the
case for full-length HGF/SF.
Our results, however, do raise the question of the physio-
logical function of HGF/SF binding to HSPGs. The in
vivo data presented here suggest a role for HSPGs in pro-
moting the internalisation and degradation of HGF/SF in
tissues (Figure 8a,b). HSPGs may therefore represent a
means of clearing HGF/SF in vivo: indeed, there is a strik-
ing parallel between the increased DNA synthesis activity
of HP1 in liver (Figure 8c) and the increased level of
factor in the tissue (Figure 8b). It is possible to speculate
on other roles for HSPGs. For example, HSPGs may help
to localise HGF/SF to selected cell or tissue compart-
ments, as required for the establishment of a ‘morphogen
gradient’ during embryogenesis [43,44]. An example of
this process may be the developing limb, where migration
of myogenic precursor cells in the bud is known to
depend critically on HGF/SF and Met [45]. Membrane
and matrix HSPGs may also provide a storage compart-
ment for HGF/SF. 
Applications of heparin-deficient HGF/SF mutants in vivo
Considerable interest has recently arisen in potential ther-
apeutic applications of HGF/SF because the factor pro-
motes liver [46] and kidney [47] regeneration after injury.
HGF/SF is cleared very rapidly from the circulation
[23,34,35]. The half-life of the growth factor in plasma can
be extended by binding it to either heparin [23] or other
polyanions, such as dextran sulphates [48], however, and
HGF/SF infused as a complex with dextran sulphate has
significantly higher activity in inducing hepatocyte prolif-
eration in adult animals [48]. Our work demonstrates that
equal or superior results can be achieved with engineered
forms of HGF/SF, such as the HP1 mutant. The mutant is
present in the circulation for a longer amount of time
(Figure 8a), is present in tissues at greater levels (Figure
8b) and is more active than wt-HGF/SF in inducing DNA
synthesis in adult liver (Figure 8c). Mutants such as HP1
may thus extend and enhance the therapeutic applications
of HGF/SF.
Materials and methods
Cell lines
Cell lines were either purchased from ATCC or are as previously
described in [7] and [49]. Cells were routinely grown in DMEM supp-
lemented with 10% fetal calf serum at 37°C and 10% CO2. 
In vitro mutagenesis of the hairpin structure and kringle 2
A double stranded oligonucleotide (5′-CACAGTCAGGACATCAT-
CATCATCATCATTAAGGATCCTCTAGAGGTAC-3′) coding for six
histidine residues and a stop codon was cloned into the KpnI restric-
tion site of the 2.2 kb BamHI–KpnI fragment of the HGF/SF cDNA. In
initial experiments, a cDNA encoding wt-HGF/SF fused to a carboxy-
terminal haemagglutinin tag was used [26]. For the generation of point
mutants of the hairpin structure or kringle 2, codon substitutions were
introduced into the cDNA by annealing mismatched primers in PCR
reactions. The PCR fragments were cloned into the cDNA and muta-
tions confirmed by sequencing. The point mutants generated in this
way are shown in Figure 1. For deletion of the hairpin structure, an
additional PstI restriction site was created at nucleotide 300 and a
fragment coding for amino acids 68–100 of HGF/SF was deleted by
partial digestion.
Transient expression of wild-type and mutant HGF/SF in
Neuro 2a cells
The cDNAs encoding mutant HGF/SFs (10 µg each) were transiently
transfected into Neuro 2a cells as described [26]. For immunoprecipi-
tation, the Neuro 2a cells were labelled overnight with 20 µCi/ml
[35S]cysteine (Amersham) 1 day after transfection, and HGF/SF was
immunoprecipitated from the supernatant (1.5 ml) using 2 µg anti-
HGF/SF antibody (clone 34) and 100 µl protein A–Sepharose 4B
beads. The precipitate was washed three times with 50 mM Tris-Cl
pH 8.5, 100 mM NaCl, 1 mM EDTA, 1 mg/ml ovalbumin and 5 g/l
Triton X-100 and used for SDS gel electrophoresis and phospho-
imager analysis.
Expression of full-length wt-HGF/SF and HP1 in insect cells
For large-scale production of wt-HGF/SF and HP1, the corresponding
cDNAs were fused to a carboxy-terminal histidine tag and cloned into
the baculovirus expression vector pVL1393. Recombinant virus was
generated by co-transfection of 2 µg expression plasmid and 0.5 µg
Baculogold-DNA (Pharmingen), plaque-purified, propagated and used
to infect 5 l batches of Sf9 cells. The wt-HGF/SF and HP1 proteins
were purified from the supernatant after extensive dialysis against PBS
and affinity chromatography on 5 ml Ni2+-chelate columns (Qiagen)
using a linear gradient of imidazole (0–0.4 M in 0.1 M NaCl, 50 mM
MES pH 6.0) followed by cation exchange chromatography [8]. The
purity of the preparations was typically 80–90% as assessed by
Coomassie-stained SDS gels. 
Expression of wt-NK2 and HP1-NK2 in P. pastoris
The cDNAs encoding wt-NK2 or HP1-NK2 were generated by PCR
amplification of regions of human HGF/SF cDNA and were cloned into
the P. pastoris expression vector pPIC 9K (Invitrogen) creating an in-
frame fusion with the α-mating signal peptide of Saccharomyces cere-
visiae. Linearised, recombinant pPIC 9K plasmids carrying wt-NK2 or
HP1-NK2 cDNAs were used for transformation of the GS115, his–
strain of P. pastoris by spheroplasting. Transformed clones were ini-
tially selected on his– plates and on G418 plates for multicopy integra-
tion [50] and selected clones used for large-scale expression. The
wt-NK2 fragment was purified on heparin–Sepharose 4B (Pharmacia)
followed by S-Sepharose (Pharmacia) using a gradient of NaCl
(0.25–1.00 M) in 0.05 M MES, pH 6.0. HP1-NK2 was purified on
S-Sepharose. Monomer and dimer species of wt-NK2 and HP1-NK2
were separated by size-exclusion chromatography on a Superdex-75
column (Pharmacia) in 0.05 MES, 0.25 M NaCl, buffer, pH 6.0. The
yield of biologically active protein was between 5–10 mg/l.
Heparin and Met ELISAs
For heparin enzyme-linked immunosorbent assay (ELISA), 200 µl high
molecular weight heparin (200 µg/ml; Sigma) was added to each well
of a 96-well plate (Nunc, Multisorp). Purified HGF/SF and super-
natants of Neuro 2a cells expressing wild-type and mutant HGF/SF
proteins were incubated for 2 h and detected with either the rabbit
anti-histidine tag antibody HA11 (Hiss diagnostics) or with an anti-
HGF/SF mouse monoclonal antibody (clone 34) followed by incuba-
tion with horseradish peroxidase (HRP)-conjugated second antibody.
For Met ELISA, a soluble fusion protein consisting of the extracellular
domain(s) of Met and the hinge, CH2 and CH3 domain of
immunoglobulin γ1 was produced (G.H., unpublished observations)
and purified by protein A–Sepharose affinity chromatography to
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approximately 80% homogeneity. After coating with full-length wt-
HGF/SF or HP1 overnight at 4°C, the Met–Fc fusion protein was
added (200 ng/ml) for 2 h followed by incubation with goat anti-human
IgG antibody and HRP-conjugated rabbit anti-goat IgG antibody. For
colour development, 0.66 mg/ml ortho-phenyl diamine in 50 mM
phospate buffer pH 6.0 was used as an HRP substrate (100 µl/well).
Heparin-binding kinetics of full-length wt-HGF/SF and HP1
and their NK2 fragments
Kinetic analysis of the binding of wild-type and mutant proteins was
carried out by SPR using a BIAcore 2000 instrument. High molecular
weight heparin (10 mg/ml; Sigma) was biotinylated with a 3-fold
excess of NHS-LC-biotin (Pierce) in 1 ml of 100 mM phosphate buffer
pH 8.0 for 1 h at room temperature. Biotinylated heparin was used for
capture on the surface of streptavidin-coated SA sensor chips. All
experiments were carried out at an operating temperature of 25°C
using PBS, 0.2 mM EDTA, 0.5 g/l NaN3, 0.05 g/l p20 detergent
(BIAcore) as running buffer (EB) at 15 µl/min. Samples were routinely
diluted in 0.2 mg/ml bovine serum albumin (BSA) in 0.2 mM EDTA that
had been pre-absorbed onto heparin–Sepharose4B (Pharmacia).
Regeneration of the surface was carried out with 10 µl 0.1 g/l SDS in
water followed by 2 × 10 µl 1 M NaCl. Finally, 15 µl 0.2 mg/ml BSA in
EB was injected to block any non-specific binding sites. Data files from
the automated analysis runs were analysed by non-linear curve fitting
[51] using the BIAcore BIAevaluation software. Protein concentrations
were measured by the BCA reagent (Pierce) and the biological activity
of each batch of protein confirmed in the MDCK assay [7]. 
Cell biological assays
Colony scatter assays of MDCK and mink lung cells were carried out
as previously described [7]. For measurement of DNA synthesis, mink
lung cells were plated at a density of 5,000–10,000 cells/well in a 24-
well plate and serum-starved by incubation in DMEM for 48 h. Different
concentrations of HGF/SF and HP1 were added and incubation con-
tinued for 24 h in DMEM containing 100 µg/ml BSA before addition of
[3H]-thymidine (1 µCi/well) and a further incubation for 16 h. Radioac-
tivity that was insoluble in 5% TCA was measured by scintillation
counting after solubilisation in 0.2 M NaOH.
Total binding of wt-HGF/SF and HP1 to mink lung, HepG2
and Hep3B cells
Mink lung cells were grown to confluence in 24-well plates. After two
washes with medium, cells were incubated at 4°C for 30 min. Serial
dilutions of HGF/SF and HP1 in PBS were then added to the cells and
the cells were then incubated for 60 min at 4°C. Unbound factor was
removed by three washes with PBS and cells fixed with 4%
paraformaldheyde in PBS. After two further washes, the cells were
incubated for 15 min with a mouse anti-HGF/SF monoclonal antibody
(clone 34), which reacted in an identical manner with wt-HGF/SF and
HP1, followed by incubation for a further 15 min with fluorescein
isothiocyanate-conjugated anti-mouse IgG. A similar procedure was
followed for measuring the total binding of wt-HGF/SF and HP1 to
HepG2 and Hep3B cells except that the cells were cultured in dishes
instead of 24-well plates and binding was assessed by fluorescence
microscopy.
Clearance and tissue distribution of wt-HGF/SF and HP1 in
rats
Pure HGF/SF and HP1 (10 µg) were iodinated by a solid-phase
method using Iodogen (Pierce) by Biotez. After the reaction, 1 mg/ml
BSA was added and free iodine was removed by multiple filtration on a
Centrisat filtration apparatus (Sartorius) with a 30 kDa cut-off point.
The specific activities were calculated to be 1.85 MBq/mg for HGF/SF
and 1.95 MBq/mg for HP1. The biological activities of the proteins
before and after iodination was compared in a motility assay using
MDCK cells and determined to be 80% after iodination. Adult rats
(three per group) were anaesthetised, a catheter implanted into the
jugular vein and a single intravenous bolus injection of 0.2 ml of [125I]-
HGF/SF was given (0.45 MBq for wt-HGF/SF and 0.38 MBq for HP1
per animal). After 1, 3, 5, 7, 10 and 60 min, 2 h and 20 h, 200 µl
samples of blood were taken via the catheter. Blood was allowed to
clot and was centrifuged at 10,000 × g for 5 min at 4°C. For each
sample, 100 µl was diluted with an equal volume of PBS and 2 ml ice-
cold 10% TCA was added. After 30 min on ice, samples were cen-
trifuged and the precipitates washed with 5% TCA before counting.
For measurement of tissue radioactivity, animals were sacrificed 2 h
after injection of [125I]-labelled wt-HGF/SF or HP1 and perfused with
PBS. Organs were taken out, weighed, homogenised and the amount
of TCA-precipitatable radioactivity determined.
Effect of wt-HGF/SF and HP1 on DNA synthesis in adult liver
The ability of wild-type HGF/SF and HP1 to induce DNA synthesis in
liver cells was measured following intravenous administration of recom-
binant proteins and cell labelling with BrdU. Briefly, female animals
(6–8 weeks old; 19.5–26.9 g body weight) were injected twice daily
with either PBS, wild-type HGF/SF or HP1 in the tail vein
(55.5 µg/dose) for three days. At the time of the last injection of factor,
each animal received BrdU (75 µg/g body weight) was injected
intraperitoneally and 12 h later the animals were sacrificed, the liver
was dissected and frozen sections were prepared. Sections were fixed
in 70% ethanol (5 min), treated with 2.4 M HCl for 10 min at 37°C and
nuclei that had incorporated BrdU were stained with anti-BrdU anti-
body (Sigma, 1:400) followed by peroxidase-conjugated anti-mouse
IgG (Jackson Laboratories, 1:500). 
Supplementary material available
A figure showing BIAcore analysis of wt-HGF/SF and HP1 binding to
immobilised heparin is published with this paper on the internet.
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S1Supplementary material
Figure S1
BIAcore analysis of wt-HGF/SF and HP1 binding to immobilised
heparin. (a) A sensorgram overlay of wt-HGF/SF (4–80 nM) binding to
a heparin surface. (b) A corresponding set of sensorgrams for HP1. A
surface with higher maximum binding capacity was used for HP1
because of the differences in kinetics and binding affinity. Some curves
are omitted for clarity.
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